Identification

Name
Sipuleucel-T
Accession Number
DB06688
Type
Biotech
Groups
Approved
Biologic Classification
Cell transplant therapies
Autologous cell transplant
Description

Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared specifically for each patient. In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data). Sipuleucel-T is marketed under the brand name Provenge by Dendreon Corporation. Sipuleucel-T was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC). The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014.

Synonyms
  • Sipuleucel-T
External IDs
APC 8015 / APC8015
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ProvengeInjection50000000 1/1IntravenousDendreon2010-04-29Not applicableUs
Categories
UNII
8Q622VDR18
CAS number
917381-47-6

Pharmacology

Indication

Sipuleucel-T is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.

Structured Indications
Pharmacodynamics
Not Available
Mechanism of action

Sipuleucel-T is designed to induce an immune response targeted against PAP, an antigen expressed in most prostate cancers. During ex vivo culture with PAP-GM-CSF, APCs take up and process the recombinant target antigen into small peptides that are then displayed on the APC surface. The precise mechanism remains unknown, however.

TargetActionsOrganism
UProstatic acid phosphatase
antagonist
inhibitory immune response
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2-MethoxyethanolThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with 2-Methoxyethanol.Experimental
AbataceptThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Abatacept.Approved
AbetimusThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with abetimus.Investigational
ActeosideThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Acteoside.Investigational
AdalimumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Adalimumab.Approved
AdefovirThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Adefovir.Investigational
AfelimomabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Afelimomab.Investigational
AlefaceptThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Alefacept.Approved, Investigational, Withdrawn
AlemtuzumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Alemtuzumab.Approved, Investigational
AlicaforsenThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Alicaforsen.Investigational
AltretamineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Altretamine.Approved
AmsacrineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Amsacrine.Approved
AnakinraThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Anakinra.Approved
Antilymphocyte immunoglobulin (horse)The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).Approved
Antithymocyte immunoglobulin (rabbit)The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Antithymocyte immunoglobulin (rabbit).Approved
ApremilastThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Apremilast.Approved, Investigational
AzacitidineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Azacitidine.Approved, Investigational
AzathioprineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Azathioprine.Approved
BasiliximabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Basiliximab.Approved, Investigational
BegelomabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Begelomab.Experimental, Investigational
BelataceptThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Belatacept.Approved
BelimumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Belimumab.Approved
BenznidazoleThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Benznidazole.Approved, Investigational
BetamethasoneThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Betamethasone.Approved, Vet Approved
BleomycinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Bleomycin.Approved
BlinatumomabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Blinatumomab.Approved
Brentuximab vedotinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Brentuximab vedotin.Approved
BriakinumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Briakinumab.Investigational
BrodalumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Brodalumab.Approved, Investigational
BudesonideThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Budesonide.Approved
BusulfanThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Busulfan.Approved, Investigational
CabazitaxelThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cabazitaxel.Approved
CanakinumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Canakinumab.Approved, Investigational
CapecitabineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Capecitabine.Approved, Investigational
CarboplatinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Carboplatin.Approved
CarmustineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Carmustine.Approved
CastanospermineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Castanospermine.Experimental
Certolizumab pegolThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Certolizumab pegol.Approved
ChlorambucilThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Chlorambucil.Approved
CisplatinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cisplatin.Approved
CladribineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cladribine.Approved, Investigational
ClofarabineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Clofarabine.Approved, Investigational
CorticotropinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Corticotropin.Approved, Vet Approved
Cortisone acetateThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cortisone acetate.Approved
CyclophosphamideThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cyclophosphamide.Approved, Investigational
CyclosporineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cyclosporine.Approved, Investigational, Vet Approved
CytarabineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Cytarabine.Approved, Investigational
DacarbazineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dacarbazine.Approved, Investigational
DaclizumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Daclizumab.Approved, Investigational
DactinomycinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dactinomycin.Approved
DasatinibThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dasatinib.Approved, Investigational
DaunorubicinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Daunorubicin.Approved
DeflazacortThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Deflazacort.Approved
DeoxyspergualinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Deoxyspergualin.Investigational
DexamethasoneThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dexamethasone.Approved, Investigational, Vet Approved
Dimethyl fumarateThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dimethyl fumarate.Approved, Investigational
DinutuximabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Dinutuximab.Approved
DocetaxelThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Docetaxel.Approved, Investigational
DoxifluridineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Doxifluridine.Investigational
DoxorubicinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Doxorubicin.Approved, Investigational
EculizumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Eculizumab.Approved, Investigational
EfalizumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Efalizumab.Approved, Investigational
EpirubicinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Epirubicin.Approved
EstramustineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Estramustine.Approved
EtanerceptThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Etanercept.Approved, Investigational
EtoposideThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Etoposide.Approved
EverolimusThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Everolimus.Approved
FingolimodThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Fingolimod.Approved, Investigational
FloxuridineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Floxuridine.Approved
FludarabineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Fludarabine.Approved
FludrocortisoneThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Fludrocortisone.Approved
FluorouracilThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Fluorouracil.Approved
Gallium nitrateThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Gallium nitrate.Approved, Investigational
GemcitabineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Gemcitabine.Approved
Gemtuzumab ozogamicinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Gemtuzumab ozogamicin.Approved
Glatiramer AcetateThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Glatiramer Acetate.Approved, Investigational
GlimepirideThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Glimepiride.Approved
GolimumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Golimumab.Approved
GS 0573The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with GS 0573.Investigational
GusperimusThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Gusperimus.Investigational
Human C1-esterase inhibitorThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Human C1-esterase inhibitor.Approved
HydrocortisoneThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Hydrocortisone.Approved, Vet Approved
HydroxyureaThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Hydroxyurea.Approved
HypericinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Hypericin.Investigational
Ibritumomab tiuxetanThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ibritumomab tiuxetan.Approved
IbrutinibThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ibrutinib.Approved
IcatibantThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Icatibant.Approved
IdarubicinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Idarubicin.Approved
IdelalisibThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Idelalisib.Approved
IfosfamideThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ifosfamide.Approved
ImatinibThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Imatinib.Approved
ImiquimodThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Imiquimod.Approved, Investigational
InfliximabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Infliximab.Approved
IrinotecanThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Irinotecan.Approved, Investigational
L-PhenylalanineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with L-Phenylalanine.Approved, Nutraceutical
LeflunomideThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Leflunomide.Approved, Investigational
LenalidomideThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Lenalidomide.Approved
LisofyllineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Lisofylline.Investigational
LomustineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Lomustine.Approved
MechlorethamineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mechlorethamine.Approved
MelphalanThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Melphalan.Approved
MepolizumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mepolizumab.Approved, Investigational
MercaptopurineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mercaptopurine.Approved
MethotrexateThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Methotrexate.Approved
MethylprednisoloneThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Methylprednisolone.Approved, Vet Approved
MitomycinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mitomycin.Approved
MitoxantroneThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mitoxantrone.Approved, Investigational
MizoribineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mizoribine.Investigational
MuromonabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Muromonab.Approved, Investigational
Mycophenolate mofetilThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Mycophenolic acid.Approved
NafamostatThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Nafamostat.Approved, Investigational
NatalizumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Natalizumab.Approved, Investigational
NelarabineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Nelarabine.Approved, Investigational
NilotinibThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Nilotinib.Approved, Investigational
ObinutuzumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Obinutuzumab.Approved
OxaliplatinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Oxaliplatin.Approved, Investigational
PaclitaxelThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Paclitaxel.Approved, Vet Approved
PalbociclibThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Palbociclib.Approved
PanobinostatThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Panobinostat.Approved, Investigational
PaquinimodThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Paquinimod.Investigational
PazopanibThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pazopanib.Approved
PegaspargaseThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pegaspargase.Approved, Investigational
PemetrexedThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pemetrexed.Approved, Investigational
PentostatinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pentostatin.Approved, Investigational
PimecrolimusThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PirarubicinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pirarubicin.Investigational
PirfenidoneThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pirfenidone.Approved, Investigational
PomalidomideThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pomalidomide.Approved
PralatrexateThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Pralatrexate.Approved
PrednisoloneThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Prednisolone.Approved, Vet Approved
PrednisoneThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Prednisone.Approved, Vet Approved
ProcarbazineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Procarbazine.Approved
RilonaceptThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Rilonacept.Approved
RituximabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Rituximab.Approved
RuxolitinibThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ruxolitinib.Approved
SecukinumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Secukinumab.Approved
SemapimodThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Semapimod.Investigational
SeocalcitolThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Seocalcitol.Experimental, Investigational
SiltuximabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Siltuximab.Approved
SirolimusThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Sirolimus.Approved, Investigational
SorafenibThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Sorafenib.Approved, Investigational
SteproninThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Stepronin.Approved
StreptozocinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Streptozocin.Approved
SunitinibThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Sunitinib.Approved, Investigational
TacrolimusThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tacrolimus.Approved, Investigational
TemozolomideThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Temozolomide.Approved, Investigational
TemsirolimusThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Temsirolimus.Approved
TeniposideThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Teniposide.Approved
TepoxalinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tepoxalin.Vet Approved
TeriflunomideThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Teriflunomide.Approved
ThalidomideThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Thalidomide.Approved, Investigational, Withdrawn
ThiotepaThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Thiotepa.Approved
TioguanineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tioguanine.Approved
TocilizumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tocilizumab.Approved
TofacitinibThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tofacitinib.Approved, Investigational
TopotecanThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Topotecan.Approved, Investigational
TositumomabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tositumomab.Approved, Investigational
TrabectedinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Trabectedin.Approved, Investigational
Trastuzumab emtansineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Trastuzumab emtansine.Approved
TretinoinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Triamcinolone.Approved, Vet Approved
TriptolideThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Triptolide.Investigational
TrofosfamideThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Trofosfamide.Investigational
UstekinumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Ustekinumab.Approved, Investigational
VedolizumabThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Vedolizumab.Approved
VilanterolThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Vilanterol.Approved
VinblastineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Vinblastine.Approved
VincristineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Vincristine.Approved, Investigational
VindesineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Vindesine.Approved, Investigational
VinorelbineThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Vinorelbine.Approved, Investigational
VoclosporinThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Voclosporin.Investigational
Food Interactions
Not Available

References

General References
  1. Authors unspecified: Sipuleucel-T: APC 8015, APC-8015, prostate cancer vaccine--Dendreon. Drugs R D. 2006;7(3):197-201. [PubMed:16752945]
  2. Mulders PF, De Santis M, Powles T, Fizazi K: Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. Cancer Immunol Immunother. 2015 Jun;64(6):655-63. doi: 10.1007/s00262-015-1707-3. Epub 2015 May 30. [PubMed:26025563]
  3. Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, Richardson RL, Valone FH, Vuk-Pavlovic S: Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate. 2004 Aug 1;60(3):197-204. [PubMed:15176049]
  4. Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ: Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer. 2006 Jul 1;107(1):67-74. [PubMed:16736512]
External Links
KEGG Drug
D06644
PubChem Substance
347910360
ChEMBL
CHEMBL1237024
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Sipuleucel-T
ATC Codes
L03AX17 — Sipuleucel-t
FDA label
Download (157 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentCastrate Resistant Prostate Cancer (CRPC) / Prostate Cancer1
1RecruitingOtherProstate Cancer1
1RecruitingTreatmentMetastatic Hormone Refractory Prostate Cancer1
2Active Not RecruitingNot AvailableCastrate Refractory Metastatic Prostate Cancer (mCRPC)1
2Active Not RecruitingBasic ScienceHormone Refractory Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer1
2Active Not RecruitingBasic ScienceMetastatic Hormone Refractory Prostate Cancer1
2Active Not RecruitingTreatmentAdenocarcinoma of the Prostate / Bone Metastases / Hormone-Resistant Prostate Cancer / Recurrent Prostate Cancer / Soft Tissue Metastases / Stage IV Prostate Cancer1
2Active Not RecruitingTreatmentMetastatic Hormone Refractory Prostate Cancer1
2Active Not RecruitingTreatmentProstate Cancer1
2CompletedNot AvailableCancer of the Prostate / Prostate Cancer / Prostate Neoplasms / Prostatic Neoplasms1
2CompletedTreatmentHormone-Resistant Prostate Cancer / Metastatic Hormone Refractory Prostate Cancer / Recurrent Prostate Carcinoma / Stage IV Prostate Cancer1
2CompletedTreatmentProstate Cancer4
2CompletedTreatmentProstate Cancer / Prostatic Adenocarcinoma / Prostatic Neoplasms1
2RecruitingTreatmentMCRPC / Metastatic Castrate-Resistant Prostate Cancer1
2RecruitingTreatmentProstate Cancer2
2WithdrawnTreatmentProstate Cancer2
3CompletedTreatmentHormone-Refractory Prostate Cancer1
3CompletedTreatmentProstate Cancer3
Not AvailableActive Not RecruitingNot AvailableAdvanced Prostate Cancer / Prostatic Neoplasms1
Not AvailableRecruitingNot AvailableProstate Cancer2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
InjectionIntravenous50000000 1/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8153120No2007-03-222027-03-22Us

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
Inhibitory immune response
General Function
Thiamine phosphate phosphatase activity
Specific Function
A non-specific tyrosine phosphatase that dephosphorylates a diverse number of substrates under acidic conditions (pH 4-6) including alkyl, aryl, and acyl orthophosphate monoesters and phosphorylate...
Gene Name
ACPP
Uniprot ID
P15309
Uniprot Name
Prostatic acid phosphatase
Molecular Weight
44565.715 Da
References
  1. Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, Richardson RL, Valone FH, Vuk-Pavlovic S: Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate. 2004 Aug 1;60(3):197-204. [PubMed:15176049]
  2. Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ: Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer. 2006 Jul 1;107(1):67-74. [PubMed:16736512]
  3. Mulders PF, De Santis M, Powles T, Fizazi K: Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. Cancer Immunol Immunother. 2015 Jun;64(6):655-63. doi: 10.1007/s00262-015-1707-3. Epub 2015 May 30. [PubMed:26025563]

Drug created on March 19, 2008 10:49 / Updated on November 06, 2017 06:45